nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—CYP3A7—Rifampicin—leprosy	0.105	0.147	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Rifampicin—leprosy	0.105	0.147	CbGbCtD
Tacrolimus—CYP3A7—Dapsone—leprosy	0.087	0.121	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Dapsone—leprosy	0.087	0.121	CbGbCtD
Tacrolimus—CYP3A5—Thalidomide—leprosy	0.0816	0.114	CbGbCtD
Tacrolimus—CYP3A5—Rifampicin—leprosy	0.079	0.11	CbGbCtD
Tacrolimus—CYP3A5—Dapsone—leprosy	0.0652	0.0908	CbGbCtD
Tacrolimus—ABCB1—Rifampicin—leprosy	0.0514	0.0716	CbGbCtD
Tacrolimus—CYP3A4—Rifampicin—leprosy	0.0308	0.0429	CbGbCtD
Tacrolimus—CYP3A4—Dapsone—leprosy	0.0254	0.0354	CbGbCtD
Tacrolimus—MTOR—hindlimb—leprosy	0.00736	0.155	CbGeAlD
Tacrolimus—MTOR—appendage—leprosy	0.00631	0.133	CbGeAlD
Tacrolimus—ABCA5—eye—leprosy	0.00375	0.0788	CbGeAlD
Tacrolimus—MTOR—blood vessel—leprosy	0.00351	0.0739	CbGeAlD
Tacrolimus—ABCA5—tendon—leprosy	0.00248	0.0522	CbGeAlD
Tacrolimus—ABCA5—testis—leprosy	0.00206	0.0432	CbGeAlD
Tacrolimus—ABCA5—nervous system—leprosy	0.00202	0.0424	CbGeAlD
Tacrolimus—MTOR—eye—leprosy	0.00187	0.0393	CbGeAlD
Tacrolimus—FKBP1A—eye—leprosy	0.00168	0.0354	CbGeAlD
Tacrolimus—PPP3CA—tendon—leprosy	0.00168	0.0352	CbGeAlD
Tacrolimus—MTOR—skin of body—leprosy	0.00163	0.0342	CbGeAlD
Tacrolimus—Protein urine present—Dapsone—leprosy	0.00159	0.00715	CcSEcCtD
Tacrolimus—Altered state of consciousness—Thalidomide—leprosy	0.00157	0.00706	CcSEcCtD
Tacrolimus—Aphthous stomatitis—Thalidomide—leprosy	0.00155	0.00696	CcSEcCtD
Tacrolimus—Hernia—Thalidomide—leprosy	0.00155	0.00696	CcSEcCtD
Tacrolimus—Cerebral ischaemia—Thalidomide—leprosy	0.0015	0.00675	CcSEcCtD
Tacrolimus—Peripheral vascular disorder—Thalidomide—leprosy	0.00148	0.00665	CcSEcCtD
Tacrolimus—FKBP1A—skin of body—leprosy	0.00146	0.0308	CbGeAlD
Tacrolimus—PPP3CA—testis—leprosy	0.00139	0.0292	CbGeAlD
Tacrolimus—PPP3CA—nervous system—leprosy	0.00136	0.0286	CbGeAlD
Tacrolimus—Vesiculobullous rash—Thalidomide—leprosy	0.00129	0.00582	CcSEcCtD
Tacrolimus—Gastric ulcer—Thalidomide—leprosy	0.00125	0.00561	CcSEcCtD
Tacrolimus—Blood lactate dehydrogenase increased—Thalidomide—leprosy	0.00125	0.00561	CcSEcCtD
Tacrolimus—MTOR—tendon—leprosy	0.00124	0.026	CbGeAlD
Tacrolimus—Enlargement abdomen—Thalidomide—leprosy	0.00121	0.00542	CcSEcCtD
Tacrolimus—Deep vein thrombosis—Thalidomide—leprosy	0.00119	0.00536	CcSEcCtD
Tacrolimus—Myasthenia—Thalidomide—leprosy	0.00115	0.00519	CcSEcCtD
Tacrolimus—Hypomagnesaemia—Thalidomide—leprosy	0.00114	0.00513	CcSEcCtD
Tacrolimus—Oral candidiasis—Thalidomide—leprosy	0.00114	0.00513	CcSEcCtD
Tacrolimus—Hypothyroidism—Thalidomide—leprosy	0.00113	0.00508	CcSEcCtD
Tacrolimus—Tooth disorder—Thalidomide—leprosy	0.00112	0.00503	CcSEcCtD
Tacrolimus—Nail disorder—Thalidomide—leprosy	0.00112	0.00503	CcSEcCtD
Tacrolimus—FKBP1A—tendon—leprosy	0.00111	0.0234	CbGeAlD
Tacrolimus—Intestinal obstruction—Thalidomide—leprosy	0.00106	0.00479	CcSEcCtD
Tacrolimus—Seborrhoeic dermatitis—Thalidomide—leprosy	0.00106	0.00479	CcSEcCtD
Tacrolimus—Neuralgia—Thalidomide—leprosy	0.00104	0.00469	CcSEcCtD
Tacrolimus—Burning sensation—Thalidomide—leprosy	0.00104	0.00469	CcSEcCtD
Tacrolimus—Hypercalcaemia—Thalidomide—leprosy	0.00104	0.00469	CcSEcCtD
Tacrolimus—MTOR—testis—leprosy	0.00103	0.0216	CbGeAlD
Tacrolimus—Lung disorder—Thalidomide—leprosy	0.00103	0.00461	CcSEcCtD
Tacrolimus—Interstitial lung disease—Thalidomide—leprosy	0.00103	0.00461	CcSEcCtD
Tacrolimus—Thrombosis—Thalidomide—leprosy	0.00103	0.00461	CcSEcCtD
Tacrolimus—Nystagmus—Thalidomide—leprosy	0.00102	0.00457	CcSEcCtD
Tacrolimus—Hyperlipidaemia—Thalidomide—leprosy	0.00101	0.00453	CcSEcCtD
Tacrolimus—MTOR—nervous system—leprosy	0.00101	0.0212	CbGeAlD
Tacrolimus—Psychotic disorder—Dapsone—leprosy	0.001	0.00452	CcSEcCtD
Tacrolimus—FKBP1A—Alpha-synuclein signaling—PARK2—leprosy	0.000989	0.0858	CbGpPWpGaD
Tacrolimus—Stupor—Thalidomide—leprosy	0.000972	0.00437	CcSEcCtD
Tacrolimus—Albuminuria—Thalidomide—leprosy	0.000972	0.00437	CcSEcCtD
Tacrolimus—Cholestasis—Thalidomide—leprosy	0.000955	0.0043	CcSEcCtD
Tacrolimus—Pleural effusion—Thalidomide—leprosy	0.000948	0.00426	CcSEcCtD
Tacrolimus—Amblyopia—Thalidomide—leprosy	0.00094	0.00422	CcSEcCtD
Tacrolimus—Skin ulcer—Thalidomide—leprosy	0.000932	0.00419	CcSEcCtD
Tacrolimus—Hyperaesthesia—Thalidomide—leprosy	0.000924	0.00416	CcSEcCtD
Tacrolimus—FKBP1A—testis—leprosy	0.000922	0.0194	CbGeAlD
Tacrolimus—Rash pustular—Thalidomide—leprosy	0.00091	0.00409	CcSEcCtD
Tacrolimus—Muscular weakness—Dapsone—leprosy	0.000907	0.00408	CcSEcCtD
Tacrolimus—FKBP1A—nervous system—leprosy	0.000905	0.019	CbGeAlD
Tacrolimus—Myocardial ischaemia—Thalidomide—leprosy	0.000903	0.00406	CcSEcCtD
Tacrolimus—Influenza—Dapsone—leprosy	0.000889	0.004	CcSEcCtD
Tacrolimus—Endocrine disorder—Thalidomide—leprosy	0.000875	0.00393	CcSEcCtD
Tacrolimus—Pancreatitis—Dapsone—leprosy	0.000872	0.00392	CcSEcCtD
Tacrolimus—Acne—Thalidomide—leprosy	0.000862	0.00388	CcSEcCtD
Tacrolimus—Jaundice cholestatic—Thalidomide—leprosy	0.000826	0.00371	CcSEcCtD
Tacrolimus—Proteinuria—Thalidomide—leprosy	0.000826	0.00371	CcSEcCtD
Tacrolimus—Accidental injury—Thalidomide—leprosy	0.00082	0.00369	CcSEcCtD
Tacrolimus—Protein urine present—Thalidomide—leprosy	0.000814	0.00366	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Dapsone—leprosy	0.000812	0.00365	CcSEcCtD
Tacrolimus—Skin discolouration—Thalidomide—leprosy	0.000803	0.00361	CcSEcCtD
Tacrolimus—Bone disorder—Thalidomide—leprosy	0.000803	0.00361	CcSEcCtD
Tacrolimus—Cellulitis—Thalidomide—leprosy	0.000798	0.00359	CcSEcCtD
Tacrolimus—Hyperbilirubinaemia—Thalidomide—leprosy	0.000798	0.00359	CcSEcCtD
Tacrolimus—Arthropathy—Thalidomide—leprosy	0.000798	0.00359	CcSEcCtD
Tacrolimus—Hypocalcaemia—Thalidomide—leprosy	0.000793	0.00356	CcSEcCtD
Tacrolimus—Thinking abnormal—Thalidomide—leprosy	0.000793	0.00356	CcSEcCtD
Tacrolimus—Oliguria—Thalidomide—leprosy	0.000787	0.00354	CcSEcCtD
Tacrolimus—Herpes simplex—Thalidomide—leprosy	0.000787	0.00354	CcSEcCtD
Tacrolimus—Hyperuricaemia—Thalidomide—leprosy	0.000782	0.00352	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Dapsone—leprosy	0.000777	0.00349	CcSEcCtD
Tacrolimus—Leukocytosis—Thalidomide—leprosy	0.000772	0.00347	CcSEcCtD
Tacrolimus—Hypercholesterolaemia—Thalidomide—leprosy	0.000767	0.00345	CcSEcCtD
Tacrolimus—Hearing impaired—Thalidomide—leprosy	0.000762	0.00343	CcSEcCtD
Tacrolimus—Creatinine increased—Thalidomide—leprosy	0.000762	0.00343	CcSEcCtD
Tacrolimus—Sinusitis—Dapsone—leprosy	0.000744	0.00334	CcSEcCtD
Tacrolimus—PPP3CA—T-Cell Receptor and Co-stimulatory Signaling—CD8A—leprosy	0.000744	0.0645	CbGpPWpGaD
Tacrolimus—Coordination abnormal—Thalidomide—leprosy	0.000739	0.00332	CcSEcCtD
Tacrolimus—Blood uric acid increased—Thalidomide—leprosy	0.000739	0.00332	CcSEcCtD
Tacrolimus—Neck pain—Thalidomide—leprosy	0.000734	0.0033	CcSEcCtD
Tacrolimus—ABCB1—blood vessel—leprosy	0.000731	0.0154	CbGeAlD
Tacrolimus—Phosphatase alkaline increased—Thalidomide—leprosy	0.000726	0.00326	CcSEcCtD
Tacrolimus—Hepatocellular injury—Thalidomide—leprosy	0.000726	0.00326	CcSEcCtD
Tacrolimus—Hyperkalaemia—Thalidomide—leprosy	0.000713	0.0032	CcSEcCtD
Tacrolimus—ORM1—nervous system—leprosy	0.000709	0.0149	CbGeAlD
Tacrolimus—Pharyngitis—Dapsone—leprosy	0.000706	0.00318	CcSEcCtD
Tacrolimus—Depressed level of consciousness—Thalidomide—leprosy	0.000701	0.00315	CcSEcCtD
Tacrolimus—Colitis—Thalidomide—leprosy	0.000697	0.00313	CcSEcCtD
Tacrolimus—Candida infection—Thalidomide—leprosy	0.000693	0.00311	CcSEcCtD
Tacrolimus—Blood urea increased—Thalidomide—leprosy	0.000685	0.00308	CcSEcCtD
Tacrolimus—Neuropathy—Thalidomide—leprosy	0.000681	0.00306	CcSEcCtD
Tacrolimus—Dry eye—Thalidomide—leprosy	0.00067	0.00301	CcSEcCtD
Tacrolimus—Cramps of lower extremities—Thalidomide—leprosy	0.000667	0.003	CcSEcCtD
Tacrolimus—Tinnitus—Dapsone—leprosy	0.000664	0.00298	CcSEcCtD
Tacrolimus—Oesophagitis—Thalidomide—leprosy	0.000663	0.00298	CcSEcCtD
Tacrolimus—Rash maculo-papular—Thalidomide—leprosy	0.00066	0.00296	CcSEcCtD
Tacrolimus—Pulmonary oedema—Thalidomide—leprosy	0.000646	0.0029	CcSEcCtD
Tacrolimus—Hypertonia—Thalidomide—leprosy	0.000636	0.00286	CcSEcCtD
Tacrolimus—ALB—testis—leprosy	0.000633	0.0133	CbGeAlD
Tacrolimus—Sepsis—Thalidomide—leprosy	0.00063	0.00283	CcSEcCtD
Tacrolimus—Mental disability—Thalidomide—leprosy	0.00063	0.00283	CcSEcCtD
Tacrolimus—Erythema—Dapsone—leprosy	0.00062	0.00279	CcSEcCtD
Tacrolimus—Lymphadenopathy—Thalidomide—leprosy	0.000617	0.00278	CcSEcCtD
Tacrolimus—Thrombophlebitis—Thalidomide—leprosy	0.000608	0.00274	CcSEcCtD
Tacrolimus—Diabetes mellitus—Thalidomide—leprosy	0.000606	0.00272	CcSEcCtD
Tacrolimus—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.000606	0.00272	CcSEcCtD
Tacrolimus—Photosensitivity—Thalidomide—leprosy	0.0006	0.0027	CcSEcCtD
Tacrolimus—Gastroenteritis—Thalidomide—leprosy	0.000594	0.00267	CcSEcCtD
Tacrolimus—Deafness—Thalidomide—leprosy	0.000589	0.00265	CcSEcCtD
Tacrolimus—Eczema—Thalidomide—leprosy	0.000586	0.00263	CcSEcCtD
Tacrolimus—Vision blurred—Dapsone—leprosy	0.000584	0.00263	CcSEcCtD
Tacrolimus—Eye pain—Thalidomide—leprosy	0.000583	0.00262	CcSEcCtD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—leprosy	0.000583	0.0505	CbGpPWpGaD
Tacrolimus—Cardiac failure congestive—Thalidomide—leprosy	0.000581	0.00261	CcSEcCtD
Tacrolimus—Injury—Thalidomide—leprosy	0.000573	0.00258	CcSEcCtD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—TNFSF15—leprosy	0.000571	0.0495	CbGpPWpGaD
Tacrolimus—Renal failure acute—Thalidomide—leprosy	0.000571	0.00256	CcSEcCtD
Tacrolimus—Amnesia—Thalidomide—leprosy	0.000561	0.00252	CcSEcCtD
Tacrolimus—Increased appetite—Thalidomide—leprosy	0.000561	0.00252	CcSEcCtD
Tacrolimus—Dermatitis exfoliative—Thalidomide—leprosy	0.000558	0.00251	CcSEcCtD
Tacrolimus—Vertigo—Dapsone—leprosy	0.000557	0.0025	CcSEcCtD
Tacrolimus—Atrial fibrillation—Thalidomide—leprosy	0.000556	0.0025	CcSEcCtD
Tacrolimus—Dermatitis bullous—Thalidomide—leprosy	0.000551	0.00248	CcSEcCtD
Tacrolimus—Arthritis—Thalidomide—leprosy	0.000542	0.00244	CcSEcCtD
Tacrolimus—Cough—Dapsone—leprosy	0.000541	0.00243	CcSEcCtD
Tacrolimus—Cardiac failure—Thalidomide—leprosy	0.00054	0.00243	CcSEcCtD
Tacrolimus—Hypoglycaemia—Thalidomide—leprosy	0.00054	0.00243	CcSEcCtD
Tacrolimus—Hyponatraemia—Thalidomide—leprosy	0.000529	0.00238	CcSEcCtD
Tacrolimus—Osteoarthritis—Thalidomide—leprosy	0.000527	0.00237	CcSEcCtD
Tacrolimus—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.000527	0.00237	CcSEcCtD
Tacrolimus—Pain in extremity—Thalidomide—leprosy	0.000527	0.00237	CcSEcCtD
Tacrolimus—Migraine—Thalidomide—leprosy	0.000518	0.00233	CcSEcCtD
Tacrolimus—Affect lability—Thalidomide—leprosy	0.000518	0.00233	CcSEcCtD
Tacrolimus—Psychotic disorder—Thalidomide—leprosy	0.000514	0.00231	CcSEcCtD
Tacrolimus—MTOR—IL4-mediated signaling events—LTA—leprosy	0.000513	0.0445	CbGpPWpGaD
Tacrolimus—Face oedema—Thalidomide—leprosy	0.000508	0.00229	CcSEcCtD
Tacrolimus—Cardiac arrest—Thalidomide—leprosy	0.000501	0.00225	CcSEcCtD
Tacrolimus—Mood swings—Thalidomide—leprosy	0.000499	0.00224	CcSEcCtD
Tacrolimus—Tachycardia—Dapsone—leprosy	0.000494	0.00222	CcSEcCtD
Tacrolimus—Blood creatinine increased—Thalidomide—leprosy	0.000493	0.00222	CcSEcCtD
Tacrolimus—Dehydration—Thalidomide—leprosy	0.00049	0.0022	CcSEcCtD
Tacrolimus—Liver function test abnormal—Thalidomide—leprosy	0.000486	0.00219	CcSEcCtD
Tacrolimus—Dry skin—Thalidomide—leprosy	0.000483	0.00217	CcSEcCtD
Tacrolimus—Orthostatic hypotension—Thalidomide—leprosy	0.000481	0.00216	CcSEcCtD
Tacrolimus—Hypokalaemia—Thalidomide—leprosy	0.000479	0.00215	CcSEcCtD
Tacrolimus—Breast disorder—Thalidomide—leprosy	0.000476	0.00214	CcSEcCtD
Tacrolimus—Cramp muscle—Thalidomide—leprosy	0.000474	0.00213	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Thalidomide—leprosy	0.000474	0.00213	CcSEcCtD
Tacrolimus—Muscular weakness—Thalidomide—leprosy	0.000465	0.00209	CcSEcCtD
Tacrolimus—Abdominal distension—Thalidomide—leprosy	0.000458	0.00206	CcSEcCtD
Tacrolimus—Insomnia—Dapsone—leprosy	0.000457	0.00206	CcSEcCtD
Tacrolimus—Dysphagia—Thalidomide—leprosy	0.000455	0.00205	CcSEcCtD
Tacrolimus—Influenza—Thalidomide—leprosy	0.000455	0.00205	CcSEcCtD
Tacrolimus—Pancreatitis—Thalidomide—leprosy	0.000446	0.00201	CcSEcCtD
Tacrolimus—Angina pectoris—Thalidomide—leprosy	0.000443	0.00199	CcSEcCtD
Tacrolimus—Bronchitis—Thalidomide—leprosy	0.000438	0.00197	CcSEcCtD
Tacrolimus—Pancytopenia—Thalidomide—leprosy	0.000432	0.00194	CcSEcCtD
Tacrolimus—Neutropenia—Thalidomide—leprosy	0.000426	0.00191	CcSEcCtD
Tacrolimus—Pollakiuria—Thalidomide—leprosy	0.000421	0.00189	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Thalidomide—leprosy	0.000416	0.00187	CcSEcCtD
Tacrolimus—Weight increased—Thalidomide—leprosy	0.000414	0.00186	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Dapsone—leprosy	0.000414	0.00186	CcSEcCtD
Tacrolimus—Weight decreased—Thalidomide—leprosy	0.000412	0.00185	CcSEcCtD
Tacrolimus—Hyperglycaemia—Thalidomide—leprosy	0.000411	0.00185	CcSEcCtD
Tacrolimus—Pneumonia—Thalidomide—leprosy	0.000408	0.00184	CcSEcCtD
Tacrolimus—Infestation NOS—Thalidomide—leprosy	0.000406	0.00182	CcSEcCtD
Tacrolimus—Infestation—Thalidomide—leprosy	0.000406	0.00182	CcSEcCtD
Tacrolimus—Depression—Thalidomide—leprosy	0.000405	0.00182	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000402	0.00181	CcSEcCtD
Tacrolimus—Acute coronary syndrome—Thalidomide—leprosy	0.0004	0.0018	CcSEcCtD
Tacrolimus—Body temperature increased—Dapsone—leprosy	0.0004	0.0018	CcSEcCtD
Tacrolimus—Abdominal pain—Dapsone—leprosy	0.0004	0.0018	CcSEcCtD
Tacrolimus—Renal failure—Thalidomide—leprosy	0.000399	0.00179	CcSEcCtD
Tacrolimus—Myocardial infarction—Thalidomide—leprosy	0.000398	0.00179	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Thalidomide—leprosy	0.000398	0.00179	CcSEcCtD
Tacrolimus—Stomatitis—Thalidomide—leprosy	0.000396	0.00178	CcSEcCtD
Tacrolimus—Conjunctivitis—Thalidomide—leprosy	0.000395	0.00177	CcSEcCtD
Tacrolimus—PPP3CA—T-Cell Receptor and Co-stimulatory Signaling—IL2—leprosy	0.000393	0.0341	CbGpPWpGaD
Tacrolimus—Sweating—Thalidomide—leprosy	0.000389	0.00175	CcSEcCtD
Tacrolimus—Haematuria—Thalidomide—leprosy	0.000387	0.00174	CcSEcCtD
Tacrolimus—Epistaxis—Thalidomide—leprosy	0.000383	0.00172	CcSEcCtD
Tacrolimus—Sinusitis—Thalidomide—leprosy	0.000381	0.00171	CcSEcCtD
Tacrolimus—Agranulocytosis—Thalidomide—leprosy	0.000379	0.0017	CcSEcCtD
Tacrolimus—Bradycardia—Thalidomide—leprosy	0.000371	0.00167	CcSEcCtD
Tacrolimus—Rhinitis—Thalidomide—leprosy	0.000365	0.00164	CcSEcCtD
Tacrolimus—Hepatitis—Thalidomide—leprosy	0.000364	0.00164	CcSEcCtD
Tacrolimus—Hypoaesthesia—Thalidomide—leprosy	0.000363	0.00163	CcSEcCtD
Tacrolimus—Pharyngitis—Thalidomide—leprosy	0.000362	0.00163	CcSEcCtD
Tacrolimus—Urinary tract disorder—Thalidomide—leprosy	0.00036	0.00162	CcSEcCtD
Tacrolimus—Oedema peripheral—Thalidomide—leprosy	0.000359	0.00161	CcSEcCtD
Tacrolimus—Urethral disorder—Thalidomide—leprosy	0.000357	0.00161	CcSEcCtD
Tacrolimus—Visual impairment—Thalidomide—leprosy	0.000351	0.00158	CcSEcCtD
Tacrolimus—Erythema multiforme—Thalidomide—leprosy	0.000345	0.00155	CcSEcCtD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IFNG—leprosy	0.000343	0.0297	CbGpPWpGaD
Tacrolimus—Eye disorder—Thalidomide—leprosy	0.000341	0.00153	CcSEcCtD
Tacrolimus—Tinnitus—Thalidomide—leprosy	0.00034	0.00153	CcSEcCtD
Tacrolimus—Cardiac disorder—Thalidomide—leprosy	0.000338	0.00152	CcSEcCtD
Tacrolimus—Angiopathy—Thalidomide—leprosy	0.000331	0.00149	CcSEcCtD
Tacrolimus—Immune system disorder—Thalidomide—leprosy	0.000329	0.00148	CcSEcCtD
Tacrolimus—Mediastinal disorder—Thalidomide—leprosy	0.000328	0.00148	CcSEcCtD
Tacrolimus—Chills—Thalidomide—leprosy	0.000327	0.00147	CcSEcCtD
Tacrolimus—Arrhythmia—Thalidomide—leprosy	0.000326	0.00146	CcSEcCtD
Tacrolimus—Alopecia—Thalidomide—leprosy	0.000322	0.00145	CcSEcCtD
Tacrolimus—Vomiting—Dapsone—leprosy	0.000322	0.00145	CcSEcCtD
Tacrolimus—Mental disorder—Thalidomide—leprosy	0.000319	0.00144	CcSEcCtD
Tacrolimus—Malnutrition—Thalidomide—leprosy	0.000317	0.00143	CcSEcCtD
Tacrolimus—Headache—Dapsone—leprosy	0.000317	0.00142	CcSEcCtD
Tacrolimus—Flatulence—Thalidomide—leprosy	0.000313	0.00141	CcSEcCtD
Tacrolimus—Tension—Thalidomide—leprosy	0.000311	0.0014	CcSEcCtD
Tacrolimus—Dysgeusia—Thalidomide—leprosy	0.000311	0.0014	CcSEcCtD
Tacrolimus—Nervousness—Thalidomide—leprosy	0.000308	0.00138	CcSEcCtD
Tacrolimus—Back pain—Thalidomide—leprosy	0.000307	0.00138	CcSEcCtD
Tacrolimus—Muscle spasms—Thalidomide—leprosy	0.000305	0.00137	CcSEcCtD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—leprosy	0.000305	0.0264	CbGpPWpGaD
Tacrolimus—Nausea—Dapsone—leprosy	0.0003	0.00135	CcSEcCtD
Tacrolimus—Vision blurred—Thalidomide—leprosy	0.000299	0.00134	CcSEcCtD
Tacrolimus—Tremor—Thalidomide—leprosy	0.000297	0.00134	CcSEcCtD
Tacrolimus—CYP3A4—nervous system—leprosy	0.000296	0.00622	CbGeAlD
Tacrolimus—Ill-defined disorder—Thalidomide—leprosy	0.000294	0.00132	CcSEcCtD
Tacrolimus—Anaemia—Thalidomide—leprosy	0.000293	0.00132	CcSEcCtD
Tacrolimus—Agitation—Thalidomide—leprosy	0.000291	0.00131	CcSEcCtD
Tacrolimus—Malaise—Thalidomide—leprosy	0.000286	0.00129	CcSEcCtD
Tacrolimus—Vertigo—Thalidomide—leprosy	0.000285	0.00128	CcSEcCtD
Tacrolimus—Syncope—Thalidomide—leprosy	0.000284	0.00128	CcSEcCtD
Tacrolimus—Leukopenia—Thalidomide—leprosy	0.000284	0.00128	CcSEcCtD
Tacrolimus—Palpitations—Thalidomide—leprosy	0.00028	0.00126	CcSEcCtD
Tacrolimus—Loss of consciousness—Thalidomide—leprosy	0.000279	0.00125	CcSEcCtD
Tacrolimus—Cough—Thalidomide—leprosy	0.000277	0.00124	CcSEcCtD
Tacrolimus—Convulsion—Thalidomide—leprosy	0.000275	0.00124	CcSEcCtD
Tacrolimus—Hypertension—Thalidomide—leprosy	0.000274	0.00123	CcSEcCtD
Tacrolimus—Chest pain—Thalidomide—leprosy	0.00027	0.00121	CcSEcCtD
Tacrolimus—Myalgia—Thalidomide—leprosy	0.00027	0.00121	CcSEcCtD
Tacrolimus—Arthralgia—Thalidomide—leprosy	0.00027	0.00121	CcSEcCtD
Tacrolimus—Anxiety—Thalidomide—leprosy	0.000269	0.00121	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000268	0.00121	CcSEcCtD
Tacrolimus—Discomfort—Thalidomide—leprosy	0.000267	0.0012	CcSEcCtD
Tacrolimus—Dry mouth—Thalidomide—leprosy	0.000264	0.00119	CcSEcCtD
Tacrolimus—Confusional state—Thalidomide—leprosy	0.000261	0.00117	CcSEcCtD
Tacrolimus—Oedema—Thalidomide—leprosy	0.000259	0.00116	CcSEcCtD
Tacrolimus—Infection—Thalidomide—leprosy	0.000257	0.00116	CcSEcCtD
Tacrolimus—Shock—Thalidomide—leprosy	0.000255	0.00114	CcSEcCtD
Tacrolimus—Nervous system disorder—Thalidomide—leprosy	0.000254	0.00114	CcSEcCtD
Tacrolimus—Thrombocytopenia—Thalidomide—leprosy	0.000253	0.00114	CcSEcCtD
Tacrolimus—Tachycardia—Thalidomide—leprosy	0.000253	0.00114	CcSEcCtD
Tacrolimus—Skin disorder—Thalidomide—leprosy	0.000251	0.00113	CcSEcCtD
Tacrolimus—Hyperhidrosis—Thalidomide—leprosy	0.00025	0.00112	CcSEcCtD
Tacrolimus—Anorexia—Thalidomide—leprosy	0.000247	0.00111	CcSEcCtD
Tacrolimus—Hypotension—Thalidomide—leprosy	0.000242	0.00109	CcSEcCtD
Tacrolimus—MTOR—IL12-mediated signaling events—RIPK2—leprosy	0.000239	0.0207	CbGpPWpGaD
Tacrolimus—Musculoskeletal discomfort—Thalidomide—leprosy	0.000236	0.00106	CcSEcCtD
Tacrolimus—Insomnia—Thalidomide—leprosy	0.000234	0.00105	CcSEcCtD
Tacrolimus—Paraesthesia—Thalidomide—leprosy	0.000232	0.00104	CcSEcCtD
Tacrolimus—Dyspnoea—Thalidomide—leprosy	0.000231	0.00104	CcSEcCtD
Tacrolimus—PPP3CA—Amyotrophic lateral sclerosis (ALS)—TNF—leprosy	0.000231	0.02	CbGpPWpGaD
Tacrolimus—Somnolence—Thalidomide—leprosy	0.00023	0.00103	CcSEcCtD
Tacrolimus—Dyspepsia—Thalidomide—leprosy	0.000228	0.00102	CcSEcCtD
Tacrolimus—Decreased appetite—Thalidomide—leprosy	0.000225	0.00101	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Thalidomide—leprosy	0.000224	0.001	CcSEcCtD
Tacrolimus—Fatigue—Thalidomide—leprosy	0.000223	0.001	CcSEcCtD
Tacrolimus—Pain—Thalidomide—leprosy	0.000221	0.000995	CcSEcCtD
Tacrolimus—Constipation—Thalidomide—leprosy	0.000221	0.000995	CcSEcCtD
Tacrolimus—Feeling abnormal—Thalidomide—leprosy	0.000213	0.000959	CcSEcCtD
Tacrolimus—ABCB1—testis—leprosy	0.000213	0.00449	CbGeAlD
Tacrolimus—Gastrointestinal pain—Thalidomide—leprosy	0.000212	0.000952	CcSEcCtD
Tacrolimus—ABCB1—nervous system—leprosy	0.000209	0.0044	CbGeAlD
Tacrolimus—FKBP1A—TGF-beta Receptor Signaling—IFNG—leprosy	0.000208	0.0181	CbGpPWpGaD
Tacrolimus—Urticaria—Thalidomide—leprosy	0.000206	0.000924	CcSEcCtD
Tacrolimus—Abdominal pain—Thalidomide—leprosy	0.000205	0.00092	CcSEcCtD
Tacrolimus—Body temperature increased—Thalidomide—leprosy	0.000205	0.00092	CcSEcCtD
Tacrolimus—Hypersensitivity—Thalidomide—leprosy	0.000191	0.000857	CcSEcCtD
Tacrolimus—Asthenia—Thalidomide—leprosy	0.000186	0.000835	CcSEcCtD
Tacrolimus—Pruritus—Thalidomide—leprosy	0.000183	0.000823	CcSEcCtD
Tacrolimus—PPP3CA—C-MYB transcription factor network—CD4—leprosy	0.000182	0.0158	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—CD8A—leprosy	0.000181	0.0157	CbGpPWpGaD
Tacrolimus—MTOR—IL4-mediated signaling events—CD40LG—leprosy	0.000179	0.0155	CbGpPWpGaD
Tacrolimus—MTOR—IL4-mediated signaling events—IL10—leprosy	0.000179	0.0155	CbGpPWpGaD
Tacrolimus—Diarrhoea—Thalidomide—leprosy	0.000177	0.000796	CcSEcCtD
Tacrolimus—PPP3CA—Cardiac Hypertrophic Response—TNF—leprosy	0.000172	0.0149	CbGpPWpGaD
Tacrolimus—Dizziness—Thalidomide—leprosy	0.000171	0.00077	CcSEcCtD
Tacrolimus—Vomiting—Thalidomide—leprosy	0.000165	0.00074	CcSEcCtD
Tacrolimus—Rash—Thalidomide—leprosy	0.000163	0.000734	CcSEcCtD
Tacrolimus—Dermatitis—Thalidomide—leprosy	0.000163	0.000733	CcSEcCtD
Tacrolimus—Headache—Thalidomide—leprosy	0.000162	0.000729	CcSEcCtD
Tacrolimus—MTOR—Type II diabetes mellitus—TNF—leprosy	0.000156	0.0135	CbGpPWpGaD
Tacrolimus—Nausea—Thalidomide—leprosy	0.000154	0.000691	CcSEcCtD
Tacrolimus—MTOR—IL12-mediated signaling events—HLA-DRB1—leprosy	0.000148	0.0128	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—IFNG—leprosy	0.000144	0.0125	CbGpPWpGaD
Tacrolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—leprosy	0.000141	0.0122	CbGpPWpGaD
Tacrolimus—MTOR—IFN-gamma pathway—IFNG—leprosy	0.000141	0.0122	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CYLD—leprosy	0.000139	0.0121	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—leprosy	0.000135	0.0117	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—HLA-DRB1—leprosy	0.000134	0.0116	CbGpPWpGaD
Tacrolimus—PPP3CA—Alzheimers Disease—TNF—leprosy	0.000128	0.0111	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—IL2—leprosy	0.000128	0.0111	CbGpPWpGaD
Tacrolimus—PPP3CA—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	0.000122	0.0106	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—HLA-DRB1—leprosy	0.000113	0.00978	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—IFNG—leprosy	0.000112	0.00967	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—IFNG—leprosy	0.000108	0.00934	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—CD4—leprosy	0.000104	0.00902	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—IL2—leprosy	9.91e-05	0.00859	CbGpPWpGaD
Tacrolimus—MTOR—Regulation of Telomerase—IFNG—leprosy	9.75e-05	0.00845	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—IL2—leprosy	9.58e-05	0.0083	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—CD4—leprosy	9.42e-05	0.00816	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—TNF—leprosy	9.31e-05	0.00807	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—RIPK2—leprosy	8.97e-05	0.00777	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—TLR2—leprosy	8.97e-05	0.00777	CbGpPWpGaD
Tacrolimus—MTOR—Regulation of Telomerase—IL2—leprosy	8.67e-05	0.00751	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—NOD2—leprosy	8.13e-05	0.00705	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CYLD—leprosy	8.11e-05	0.00703	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—CD4—leprosy	7.95e-05	0.00689	CbGpPWpGaD
Tacrolimus—MTOR—Cardiac Hypertrophic Response—TNF—leprosy	7.48e-05	0.00648	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—TNF—leprosy	7.22e-05	0.00626	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—PARK2—leprosy	7.17e-05	0.00621	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—TNF—leprosy	7.02e-05	0.00609	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—leprosy	6.89e-05	0.00597	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—RIPK2—leprosy	6.86e-05	0.00594	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—SLC11A1—leprosy	6.62e-05	0.00574	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CD40LG—leprosy	6.33e-05	0.00549	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL10—leprosy	6.33e-05	0.00549	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CYLD—leprosy	6.07e-05	0.00526	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—IFNG—leprosy	6.03e-05	0.00523	CbGpPWpGaD
Tacrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	5.33e-05	0.00462	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—TLR2—leprosy	5.22e-05	0.00453	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—RIPK2—leprosy	5.22e-05	0.00453	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PARK2—leprosy	5.15e-05	0.00447	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—SLC11A1—leprosy	5.13e-05	0.00445	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—HLA-DRB1—leprosy	5.1e-05	0.00442	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC11A1—leprosy	4.99e-05	0.00432	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—leprosy	4.91e-05	0.00426	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IFNG—leprosy	4.91e-05	0.00425	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—NOD2—leprosy	4.74e-05	0.00411	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IL2—leprosy	4.36e-05	0.00378	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD40LG—leprosy	4e-05	0.00347	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD8A—leprosy	3.96e-05	0.00343	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—RIPK2—leprosy	3.91e-05	0.00339	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—TLR2—leprosy	3.91e-05	0.00339	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—TNF—leprosy	3.9e-05	0.00338	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CD4—leprosy	3.9e-05	0.00338	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IFNG—leprosy	3.9e-05	0.00338	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—RIPK2—leprosy	3.76e-05	0.00326	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IFNG—leprosy	3.72e-05	0.00323	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—NOD2—leprosy	3.55e-05	0.00307	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CYLD—leprosy	3.53e-05	0.00306	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RIPK2—leprosy	3.38e-05	0.00293	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL2—leprosy	3.31e-05	0.00287	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-DRB1—leprosy	3.22e-05	0.00279	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TNF—leprosy	3.18e-05	0.00275	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PARK2—leprosy	3.12e-05	0.00271	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SLC11A1—leprosy	2.88e-05	0.0025	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD40LG—leprosy	2.88e-05	0.0025	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD8A—leprosy	2.85e-05	0.00247	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RIPK2—leprosy	2.62e-05	0.00227	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—SDHD—leprosy	2.54e-05	0.0022	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC11A1—leprosy	2.53e-05	0.0022	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—TNF—leprosy	2.52e-05	0.00219	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—TNF—leprosy	2.41e-05	0.00209	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IFNG—leprosy	2.35e-05	0.00204	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-DRB1—leprosy	2.32e-05	0.00201	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL2—leprosy	2.29e-05	0.00198	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—TLR2—leprosy	2.28e-05	0.00197	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—RIPK2—leprosy	2.28e-05	0.00197	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD4—leprosy	2.27e-05	0.00197	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC11A1—leprosy	2.22e-05	0.00193	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CD4—leprosy	2.1e-05	0.00182	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL2—leprosy	2.09e-05	0.00181	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NOD2—leprosy	2.06e-05	0.00179	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SDHD—leprosy	1.83e-05	0.00159	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD40LG—leprosy	1.75e-05	0.00151	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD8A—leprosy	1.73e-05	0.0015	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CD4—leprosy	1.7e-05	0.00148	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IL2—leprosy	1.66e-05	0.00144	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD4—leprosy	1.63e-05	0.00142	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CD4—leprosy	1.63e-05	0.00141	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SDHD—leprosy	1.58e-05	0.00137	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RIPK2—leprosy	1.47e-05	0.00128	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-DRB1—leprosy	1.41e-05	0.00122	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SDHD—leprosy	1.38e-05	0.0012	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL2—leprosy	1.35e-05	0.00117	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—leprosy	1.19e-05	0.00103	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2—leprosy	1.05e-05	0.000909	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IFNG—leprosy	1.03e-05	0.00089	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD4—leprosy	9.91e-06	0.00086	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD4—leprosy	9.15e-06	0.000794	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2—leprosy	9.12e-06	0.000791	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2—leprosy	8.55e-06	0.000741	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SDHD—leprosy	8.53e-06	0.000739	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2—leprosy	5.9e-06	0.000511	CbGpPWpGaD
